An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

Some four years af­ter it re­port­ed its first batch of piv­otal tri­al da­ta, Tetraphase fi­nal­ly se­cured FDA ap­proval for its lead an­tibi­ot­ic, er­ava­cy­cline, for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA